Grafting of human spinal stem cells into ALS rats best with immunosuppressant combination

A team of researchers grafting human spinal stem cells into rats modeled with amyotrophic lateral sclerosis (ALS), also known as "Lou Gehrig's Disease," a degenerative, lethal, neuromuscular disease, have tested four different immunosuppressive protocols aimed at determining which regimen improved long-term therapeutic effects. Their study demonstrated that a combined, systematically delivered immunosuppression regimen of two drugs significantly improved the survival of the human spinal stem cells. Their results are published in the current issue of Cell Transplantation (20:8), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

"There are no therapeutic strategies that successfully modify ALS progression or outcome," said study corresponding author Dr. Michael P. Hefferan of the University of California-San Diego Neurodegeneration Laboratory. "Cell-based transplantation therapies have emerged as potential treatments for several neurological disorders, including ALS. However, cell graft survival seems to greatly depend on an accompanying immunosuppression regimen, yet there are differential responses to identical immunosuppressive therapies."

While the reason for this differential response is unclear, the study authors suggest that several mechanisms, including distinct types of acute and inflammatory responses, may be to blame.

Their study aimed at optimizing an immunosuppressive protocol for transplanting human into presymptomatic ALS G93A rats with the G93A superoxide dismutase (SOD1) mutation. Two drugs, tacrolimus (FK506) and mycophenolate, were used alone and in combination.

"Although FK506 has been used successfully as monotherapy in our previous studies of spinal ischemia, it failed in the present study on ALS," explained Dr. Hefferan, who speculated that inflammation played a role in the failure. "In contrast to ALS, where spinal inflammation continues and likely worsens until endstage, the traumatically-injured spinal cord is typically characterized by an acute inflammatory phase followed by a progressive loss of most inflammatory markers."

According to the researchers, the animals receiving combined immunosuppression of both FK506 and mycophenolate likely benefited from the longer half-life of mycophenolate rather than from its action.

"The addition of mycophenolate seemed to supplement inhibition of T-cell formation and led to a robust when analyzed three weeks after grafting," concluded Dr. Hefferan.

More information: Hefferan, M. P.; Johe, K.; Hazel, T.; Feldman, E. L.; Lunn, J. S.; Marsala, M. Optimization of Immunosuppressive Therapy for Spinal Grafting of Human Spinal Stem Cells in a Rat Model of ALS Cell Transplant. 20(8):1153-1161; 2011.

Provided by Cell Transplantation Center of Excellence for Aging and Brain Repair

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Genetics of ALS progression

Jun 01, 2008

An upcoming paper in the June 1 issue of G&D, from Drs. Hidenori Ichijo and Hideki Nishitoh (University of Tokyo) and colleagues, lends new and valuable insight into the genetics of ALS.

Engineered stem cells carry promising ALS therapy

Sep 16, 2008

(PhysOrg.com) -- Using adult stem cells from bone marrow as "Trojan horses"to deliver a nurturing growth factor to atrophied muscles, Wisconsin scientists have successfully slowed the progression of ALS in rats.

Spinal fluid proteins signal Lou Gehrig's disease

Jan 28, 2009

High levels of certain proteins in the spinal fluid could signal the onset of Lou Gehrig's disease, according to researchers. The discovery of these biomarkers may lead to diagnostic kits for early diagnosis, accurately measuring ...

Recommended for you

Leeches help save woman's ear after pit bull mauling

Apr 18, 2014

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments